IL296712A - Split inteins and their uses - Google Patents
Split inteins and their usesInfo
- Publication number
- IL296712A IL296712A IL296712A IL29671222A IL296712A IL 296712 A IL296712 A IL 296712A IL 296712 A IL296712 A IL 296712A IL 29671222 A IL29671222 A IL 29671222A IL 296712 A IL296712 A IL 296712A
- Authority
- IL
- Israel
- Prior art keywords
- fragment
- intein
- degron
- seq
- sope
- Prior art date
Links
- 230000017730 intein-mediated protein splicing Effects 0.000 title claims description 400
- 239000012634 fragment Substances 0.000 claims description 322
- 108090000623 proteins and genes Proteins 0.000 claims description 162
- 210000004027 cell Anatomy 0.000 claims description 133
- 108091033319 polynucleotide Proteins 0.000 claims description 118
- 102000040430 polynucleotide Human genes 0.000 claims description 118
- 239000002157 polynucleotide Substances 0.000 claims description 118
- 102000004169 proteins and genes Human genes 0.000 claims description 105
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
- 210000004900 c-terminal fragment Anatomy 0.000 claims description 77
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 75
- 241000607479 Yersinia pestis Species 0.000 claims description 55
- 241000702421 Dependoparvovirus Species 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims description 18
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 15
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 13
- 101800000716 Tumor necrosis factor, membrane form Proteins 0.000 claims description 10
- 102400000700 Tumor necrosis factor, membrane form Human genes 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 108010085220 Multiprotein Complexes Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 53
- 238000001262 western blot Methods 0.000 description 41
- 150000001413 amino acids Chemical class 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 33
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 32
- 210000004899 c-terminal region Anatomy 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 101000725027 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L11-A Proteins 0.000 description 26
- 101000725541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L11-B Proteins 0.000 description 26
- 206010011906 Death Diseases 0.000 description 21
- 108010052164 Sodium Channels Proteins 0.000 description 19
- 102000018674 Sodium Channels Human genes 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 206010011878 Deafness Diseases 0.000 description 13
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 13
- 150000001408 amides Chemical class 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 208000016354 hearing loss disease Diseases 0.000 description 13
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 12
- 231100000895 deafness Toxicity 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 102100022509 Cadherin-23 Human genes 0.000 description 10
- 101100284231 Caenorhabditis elegans his-24 gene Proteins 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 9
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 101710196902 Cadherin-23 Proteins 0.000 description 8
- 102000004510 Collagen Type VII Human genes 0.000 description 8
- 108010017377 Collagen Type VII Proteins 0.000 description 8
- 102100023149 E3 ubiquitin-protein ligase MARCHF6 Human genes 0.000 description 8
- 101000978676 Homo sapiens E3 ubiquitin-protein ligase MARCHF6 Proteins 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 101150057833 THEG gene Proteins 0.000 description 7
- 229960001948 caffeine Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 208000036318 CEP290-related ciliopathy Diseases 0.000 description 6
- 101100069975 Caenorhabditis elegans his-72 gene Proteins 0.000 description 6
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 description 6
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 6
- 102000004168 Dysferlin Human genes 0.000 description 6
- 108090000620 Dysferlin Proteins 0.000 description 6
- 101000715664 Homo sapiens Centrosomal protein of 290 kDa Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 description 5
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 5
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 description 5
- 241000011102 Thera Species 0.000 description 5
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 5
- 102100031835 Unconventional myosin-VIIa Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- -1 asl amino acid Chemical class 0.000 description 5
- 210000003793 centrosome Anatomy 0.000 description 5
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000003371 toe Anatomy 0.000 description 5
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010034789 Collagen Type XI Proteins 0.000 description 4
- 102000009736 Collagen Type XI Human genes 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101000945438 Homo sapiens Kelch domain-containing protein 2 Proteins 0.000 description 4
- 102100033609 Kelch domain-containing protein 2 Human genes 0.000 description 4
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 4
- 102100031834 Unconventional myosin-VI Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 102000014835 CACNA1H Human genes 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 description 3
- 102100027280 Fanconi anemia group A protein Human genes 0.000 description 3
- 102100028893 Hemicentin-1 Human genes 0.000 description 3
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 3
- 101000867848 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1F Proteins 0.000 description 3
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 3
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010009047 Myosin VIIa Proteins 0.000 description 3
- RAQQRQCODVNJCK-JLHYYAGUSA-N N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(E)-5-hydroxy-3-(2-hydroxyethyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCCO RAQQRQCODVNJCK-JLHYYAGUSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 102100035714 Oxygen-regulated protein 1 Human genes 0.000 description 3
- 101710123995 Protein crumbs homolog 1 Proteins 0.000 description 3
- 102100037166 Protein eyes shut homolog Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 3
- 208000027073 Stargardt disease Diseases 0.000 description 3
- 101710135144 Unconventional myosin-VI Proteins 0.000 description 3
- 102100037930 Usherin Human genes 0.000 description 3
- 102100033031 Voltage-dependent L-type calcium channel subunit alpha-1F Human genes 0.000 description 3
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 description 3
- 206010001902 amaurosis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000003027 ear inner Anatomy 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 102220260177 rs1554096651 Human genes 0.000 description 3
- 102220288810 rs1554539977 Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 102100036799 Adhesion G-protein coupled receptor V1 Human genes 0.000 description 2
- 102100022794 Bestrophin-1 Human genes 0.000 description 2
- 201000009707 Brugada syndrome 1 Diseases 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000518994 Conta Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- SNPQGCDJHZAVOB-SOMABOLJSA-N D-glucosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-SOMABOLJSA-N 0.000 description 2
- 108010054814 DNA Gyrase Proteins 0.000 description 2
- 108091066210 DnaE family Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 101710142180 Hemicentin-1 Proteins 0.000 description 2
- 241001640034 Heteropterys Species 0.000 description 2
- 101000928167 Homo sapiens Adhesion G-protein coupled receptor V1 Proteins 0.000 description 2
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 2
- 101000972491 Homo sapiens Laminin subunit alpha-2 Proteins 0.000 description 2
- 101001043326 Homo sapiens Lipoxygenase homology domain-containing protein 1 Proteins 0.000 description 2
- 101001105683 Homo sapiens Pre-mRNA-processing-splicing factor 8 Proteins 0.000 description 2
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 2
- 101001028804 Homo sapiens Protein eyes shut homolog Proteins 0.000 description 2
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 description 2
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000004493 Joubert syndrome 5 Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 208000037161 Laminin subunit alpha 2-related congenital muscular dystrophy Diseases 0.000 description 2
- 101710200519 Laminin subunit alpha-2 Proteins 0.000 description 2
- 241000985284 Leuciscus idus Species 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 102100021959 Lipoxygenase homology domain-containing protein 1 Human genes 0.000 description 2
- 201000000800 Meckel syndrome 4 Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 101100328158 Mus musculus Clmp gene Proteins 0.000 description 2
- 102100032972 Myosin-14 Human genes 0.000 description 2
- 101710115136 Myosin-14 Proteins 0.000 description 2
- 102100030743 Myosin-IIIa Human genes 0.000 description 2
- 101710191970 Myosin-IIIa Proteins 0.000 description 2
- 102100030369 Myosin-IIIb Human genes 0.000 description 2
- 101710191975 Myosin-IIIb Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 102100021231 Pre-mRNA-processing-splicing factor 8 Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 101150057388 Reln gene Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 2
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 2
- 102100040756 Rhodopsin Human genes 0.000 description 2
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 description 2
- 101150015964 Strn gene Proteins 0.000 description 2
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 2
- 102100029836 Unconventional myosin-XV Human genes 0.000 description 2
- 101710138401 Usherin Proteins 0.000 description 2
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 2
- HUMHYXGDUOGHTG-HEZXSMHISA-N alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)OC1O HUMHYXGDUOGHTG-HEZXSMHISA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- XRCFXMGQEVUZFC-UHFFFAOYSA-N anisindione Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O XRCFXMGQEVUZFC-UHFFFAOYSA-N 0.000 description 2
- 229960002138 anisindione Drugs 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 201000006948 congenital merosin-deficient muscular dystrophy 1A Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 201000006756 occult macular dystrophy Diseases 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 208000024809 pituitary adenoma 5 Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220228926 rs1064793592 Human genes 0.000 description 2
- 102200081185 rs121909273 Human genes 0.000 description 2
- 102220048309 rs138317624 Human genes 0.000 description 2
- 102220005384 rs33939620 Human genes 0.000 description 2
- 102220050044 rs587783406 Human genes 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- NWXMGUDVXFXRIG-NAOJVREFSA-N (4s,4as,5as,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2C(O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-NAOJVREFSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- BYACHAOCSIPLCM-UHFFFAOYSA-N 2-[2-[bis(2-hydroxyethyl)amino]ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCN(CCO)CCO BYACHAOCSIPLCM-UHFFFAOYSA-N 0.000 description 1
- ZXXTYLFVENEGIP-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurine-2,6-dione Chemical compound O=C1NC(N)=NC2=C1NC=N2.O=C1NC(=O)NC2=C1NC=N2 ZXXTYLFVENEGIP-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101710082414 50S ribosomal protein L12, chloroplastic Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 208000006704 Aland Island eye disease Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102100040191 Alpha-tectorin Human genes 0.000 description 1
- 206010068783 Alstroem syndrome Diseases 0.000 description 1
- 201000005932 Alstrom Syndrome Diseases 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010059027 Brugada syndrome Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100394185 Caenorhabditis elegans his-63 gene Proteins 0.000 description 1
- 101100545272 Caenorhabditis elegans zif-1 gene Proteins 0.000 description 1
- 101000947501 Camptotheca acuminata (S)-8-oxocitronellyl enol synthase CYC1 Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 244000299480 Clitocybe nuda Species 0.000 description 1
- 235000002469 Clitocybe nuda Nutrition 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102100033885 Collagen alpha-2(XI) chain Human genes 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 241000252100 Conger Species 0.000 description 1
- 102220553769 Cyclic GMP-AMP synthase_T77E_mutation Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- OYIFNHCXNCRBQI-SCSAIBSYSA-N D-2-aminoadipic acid Chemical compound OC(=O)[C@H](N)CCCC(O)=O OYIFNHCXNCRBQI-SCSAIBSYSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 102100024108 Dystrophin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241001517310 Eria Species 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102220523173 Flavin reductase (NADPH)_R22E_mutation Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 1
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 description 1
- 101710114816 Gene 41 protein Proteins 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000889766 Homo sapiens Alpha-tectorin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000710619 Homo sapiens Collagen alpha-2(XI) chain Proteins 0.000 description 1
- 101001038784 Homo sapiens E3 ubiquitin-protein ligase listerin Proteins 0.000 description 1
- 101000839060 Homo sapiens Hemicentin-1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001093143 Homo sapiens Protein transport protein Sec61 subunit gamma Proteins 0.000 description 1
- 101000854044 Homo sapiens Retinitis pigmentosa 1-like 1 protein Proteins 0.000 description 1
- 101000659545 Homo sapiens U5 small nuclear ribonucleoprotein 200 kDa helicase Proteins 0.000 description 1
- 101000761646 Homo sapiens Ubiquitin-conjugating enzyme E2 G2 Proteins 0.000 description 1
- 101001128474 Homo sapiens Unconventional myosin-VI Proteins 0.000 description 1
- 101000805941 Homo sapiens Usherin Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 1
- 102220627637 Interferon alpha-8_D5E_mutation Human genes 0.000 description 1
- 102220465289 Interferon alpha-8_S6T_mutation Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000016443 LTN1 Human genes 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 201000002502 Leber congenital amaurosis 8 Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100497505 Mus musculus Ctnnd1 gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 241000849798 Nita Species 0.000 description 1
- 101150100692 ODC gene Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 101710150924 Oxygen-regulated protein 1 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 241000208465 Proteaceae Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710151974 Protein eyes shut homolog Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100389746 Rattus norvegicus Esr1 gene Proteins 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100035670 Retinitis pigmentosa 1-like 1 protein Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 108091011168 Rhodopsin kinase GRK1 Proteins 0.000 description 1
- 241001593290 Rhodopsis Species 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101000825534 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S2 Proteins 0.000 description 1
- 101000862778 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S3 Proteins 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102220506568 Small ubiquitin-related modifier 2_K35E_mutation Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 102100036230 U5 small nuclear ribonucleoprotein 200 kDa helicase Human genes 0.000 description 1
- 102100024870 Ubiquitin-conjugating enzyme E2 G2 Human genes 0.000 description 1
- 101710135185 Unconventional myosin-XV Proteins 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 201000000466 X-linked cone-rod dystrophy 3 Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000104547 Ziziphus oenoplia Species 0.000 description 1
- 235000005505 Ziziphus oenoplia Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 201000002549 age related macular degeneration 1 Diseases 0.000 description 1
- 201000002543 age related macular degeneration 2 Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000002982 auditory neuropathy Diseases 0.000 description 1
- 208000036351 autosomal dominant otospondylomegaepiphyseal dysplasia Diseases 0.000 description 1
- 201000011387 autosomal recessive nonsyndromic deafness 21 Diseases 0.000 description 1
- 201000011350 autosomal recessive nonsyndromic deafness 37 Diseases 0.000 description 1
- 201000006254 autosomal recessive nonsyndromic deafness 53 Diseases 0.000 description 1
- 201000006140 autosomal recessive nonsyndromic deafness 77 Diseases 0.000 description 1
- 208000032893 autosomal recessive nonsyndromic hearing loss 21 Diseases 0.000 description 1
- 208000032211 autosomal recessive nonsyndromic hearing loss 37 Diseases 0.000 description 1
- 208000035237 autosomal recessive nonsyndromic hearing loss 53 Diseases 0.000 description 1
- 208000033022 autosomal recessive nonsyndromic hearing loss 77 Diseases 0.000 description 1
- 208000034661 benign familial infantile 5 seizures Diseases 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 101150038738 ble gene Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000026555 breast adenosis Diseases 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035434 childhood absence susceptibility to 6 epilepsy Diseases 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 208000003904 cone-rod dystrophy 3 Diseases 0.000 description 1
- 208000015532 congenital bilateral absence of vas deferens Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- DFWFIQKMSFGDCQ-UHFFFAOYSA-N deethylatrazine Chemical compound CC(C)NC1=NC(N)=NC(Cl)=N1 DFWFIQKMSFGDCQ-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000013686 developmental and epileptic encephalopathy, 11 Diseases 0.000 description 1
- 208000021303 developmental and epileptic encephalopathy, 42 Diseases 0.000 description 1
- 208000015656 developmental and epileptic encephalopathy, 6 Diseases 0.000 description 1
- 208000025145 developmental and epileptic encephalopathy, 62 Diseases 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 201000011274 dilated cardiomyopathy 1E Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 201000004403 episodic ataxia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000032361 familial 2 myoclonus Diseases 0.000 description 1
- 208000013087 familial febrile seizures 4 Diseases 0.000 description 1
- 208000035238 familial hemiplegic 1 migraine Diseases 0.000 description 1
- 208000013779 familial hemiplegic migraine 1 Diseases 0.000 description 1
- 208000013782 familial hemiplegic migraine 3 Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 208000014204 generalized epilepsy with febrile seizures plus 2 Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000014612 hereditary episodic ataxia Diseases 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 201000006903 long QT syndrome 3 Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000024797 otospondylomegaepiphyseal dysplasia, autosomal recessive Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000502 progressive familial heart block type IA Diseases 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000016434 protein splicing Effects 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 102220214525 rs1060502897 Human genes 0.000 description 1
- 102200009943 rs116840808 Human genes 0.000 description 1
- 102220067346 rs138630815 Human genes 0.000 description 1
- 102200067659 rs397508057 Human genes 0.000 description 1
- 102200153918 rs41303733 Human genes 0.000 description 1
- 102200027763 rs75193786 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000012216 sick sinus syndrome 1 Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000033289 type 1A progressive familial heart block Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 208000036381 Åland Islands eye disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382236.6A EP3885440A1 (en) | 2020-03-26 | 2020-03-26 | Split inteins and their uses |
| PCT/EP2021/058016 WO2021191447A1 (en) | 2020-03-26 | 2021-03-26 | Split inteins and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296712A true IL296712A (en) | 2022-11-01 |
Family
ID=70292931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296712A IL296712A (en) | 2020-03-26 | 2021-03-26 | Split inteins and their uses |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230116688A1 (enExample) |
| EP (2) | EP3885440A1 (enExample) |
| JP (1) | JP2023518596A (enExample) |
| KR (1) | KR20220160052A (enExample) |
| CN (1) | CN115698307A (enExample) |
| AU (1) | AU2021241899A1 (enExample) |
| BR (1) | BR112022019167A2 (enExample) |
| CA (1) | CA3175696A1 (enExample) |
| IL (1) | IL296712A (enExample) |
| WO (1) | WO2021191447A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019336245B2 (en) | 2018-09-07 | 2026-02-26 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| CA3152679A1 (en) * | 2019-08-28 | 2021-03-04 | The Trustees Of Princeton University | Atypical split inteins and uses thereof |
| CN116096905A (zh) | 2020-02-21 | 2023-05-09 | 阿库斯股份有限公司 | 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法 |
| EP4424714A4 (en) * | 2021-10-29 | 2025-10-15 | Shanghai Sinobay Biotechnology Co Ltd | Condition-Controlled Splicable Chimeric Antigen Receptor Molecule and Its Use |
| EP4527933A4 (en) * | 2022-05-17 | 2025-12-24 | Eye & Ent Hospital Of Fudan Univ | DUAL-SUPPORT SYSTEM FOR THE TREATMENT OF HEARING LOSS, AND ITS USE |
| KR20250141200A (ko) * | 2023-02-01 | 2025-09-26 | 알렌 인스티튜트 | 전압-게이팅 나트륨 채널 기능의 인테인 매개 재구성 |
| WO2024251077A1 (zh) | 2023-06-07 | 2024-12-12 | 北京中因科技有限公司 | 表达盒组合及其应用 |
| WO2025038955A1 (en) * | 2023-08-16 | 2025-02-20 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Systems and methods for improving safety of split intein aav mediated gene therapy |
| AU2024338787A1 (en) | 2023-09-04 | 2026-03-19 | Splicebio, Sl | Use of split intein for the treatment of scn1a associated disease |
| WO2025153705A1 (en) | 2024-01-18 | 2025-07-24 | Splicebio, Sl | Use of split intein for the treatment of myo7a-associated disease |
| WO2025193938A1 (en) * | 2024-03-13 | 2025-09-18 | Oregon Health & Science University | Delivery of type iv collagen alpha chain using a split intein dual aav vector |
| WO2026013288A1 (en) | 2024-07-12 | 2026-01-15 | Splicebio, Sl | Split intein for use in the treatment of cep290-associated disease |
| WO2026057767A1 (en) | 2024-09-13 | 2026-03-19 | Splicebio, Sl | Use of split intein for the treatment of abca3-associated disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| WO2007127428A2 (en) | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
| US20180327779A1 (en) * | 2015-03-03 | 2018-11-15 | Fondazione Telethon (IT/IT) | Multiple vector system and uses thereof |
| US11203621B2 (en) * | 2015-06-19 | 2021-12-21 | Riken | PH-responsive proteolysis probe |
| WO2017132580A2 (en) * | 2016-01-29 | 2017-08-03 | The Trustees Of Princeton University | Split inteins with exceptional splicing activity |
| JP2022512718A (ja) * | 2018-10-15 | 2022-02-07 | フォンダッツィオーネ・テレソン | インテインタンパク質及びその使用 |
-
2020
- 2020-03-26 EP EP20382236.6A patent/EP3885440A1/en active Pending
-
2021
- 2021-03-26 JP JP2022558063A patent/JP2023518596A/ja active Pending
- 2021-03-26 IL IL296712A patent/IL296712A/en unknown
- 2021-03-26 KR KR1020227037261A patent/KR20220160052A/ko active Pending
- 2021-03-26 CA CA3175696A patent/CA3175696A1/en active Pending
- 2021-03-26 CN CN202180038835.4A patent/CN115698307A/zh active Pending
- 2021-03-26 US US17/914,212 patent/US20230116688A1/en active Pending
- 2021-03-26 AU AU2021241899A patent/AU2021241899A1/en active Pending
- 2021-03-26 BR BR112022019167A patent/BR112022019167A2/pt unknown
- 2021-03-26 EP EP21713447.7A patent/EP4127194A1/en active Pending
- 2021-03-26 WO PCT/EP2021/058016 patent/WO2021191447A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023518596A (ja) | 2023-05-02 |
| CN115698307A (zh) | 2023-02-03 |
| BR112022019167A2 (pt) | 2022-11-01 |
| US20230116688A1 (en) | 2023-04-13 |
| AU2021241899A1 (en) | 2022-10-06 |
| KR20220160052A (ko) | 2022-12-05 |
| EP4127194A1 (en) | 2023-02-08 |
| WO2021191447A1 (en) | 2021-09-30 |
| EP3885440A1 (en) | 2021-09-29 |
| CA3175696A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230116688A1 (en) | Split inteins and their uses | |
| KR102240180B1 (ko) | 다중 벡터 시스템 및 이의 용도 | |
| KR20210104661A (ko) | 인테인 단백질 및 이의 용도 | |
| JP2020023503A (ja) | バイオ医薬の送達のためのエキソソーム | |
| CN113631182B (zh) | 二硫键稳定的多肽组合物和使用方法 | |
| JP2024102282A (ja) | ファージミドベクター | |
| JP2022531095A (ja) | エキソソーム及びａａｖの組成物 | |
| US20250228976A1 (en) | Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor | |
| CN111621502A (zh) | 视网膜劈裂蛋白的编码序列、其表达载体构建及其应用 | |
| KR20220110442A (ko) | 비염증성 식세포작용 유도 활성을 갖는 융합분자 | |
| CN116547000A (zh) | 经修饰的红细胞及其在递送活性剂中的用途 | |
| CN121488045A (zh) | Aav衣壳变体及其用途 | |
| WO2025011566A1 (zh) | 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法 | |
| KR20240023126A (ko) | 망막 장애 | |
| CN110699367B (zh) | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 | |
| WO2025250642A2 (en) | Transferrin receptor (tfr)-binding variable domains of a heavy chain only antibody (vhh), conjugates and uses thereof | |
| US20250099622A1 (en) | Compositions and methods for expressing therapeutics | |
| US20240269327A1 (en) | Compositions and methods for transgene expression | |
| EP4729620A1 (en) | Gene therapy vector for treating parkinson's disease and use thereof | |
| CN111518813A (zh) | 视紫红质的编码序列、其表达载体构建及其应用 | |
| JP2019146524A (ja) | 高発現かつ高機能な二重特異性抗体 | |
| WO2026052740A1 (en) | Modular platform for gene therapy | |
| HK40092158B (zh) | 一种用於过敏性疾病的基因治疗载体核酸构建体及其使用方法 | |
| HK40092158A (zh) | 一种用於过敏性疾病的基因治疗载体核酸构建体及其使用方法 | |
| WO2024261332A2 (en) | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases |